(Press-News.org) Massachusetts General Hospital (MGH) researchers – along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals – have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication in Nature Biotechnology, the investigators describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage.
"The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, MD, PhD, of the MGH Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes – an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such heart disease and cancer."
Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.
Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. Because the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location, the MGH team collaborated with Alnylam scientists who are experts in RNA-interference-based therapeutics and with MIT investigators Robert Langer, ScD, and Daniel Anderson, PhD, who have developed a nanoparticle-based system for delivering molecules to specific cellular compartments.
To make sure that their siRNA preparation targeted the right monocytes, the investigators first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets.
"These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCCR2 receptor. That makes a big difference." Nahrendorf is an assistant professor of Radiology at Harvard Medical School.
INFORMATION:
Florian Leuschner and Partha Dutta of the MGH Center for Systems Biology are co-lead authors of the paper. Additional co-authors are Rostic Gorbatov, Jessica Donahoe, Gabriel Courties, Brett Marinelli, Yoshiko Iwamoto, Virna Cortez-Retamozo, Andita Newton, Mikael Pittet, Filip Swirski and Ralph Weissleder, MGH Center for Systems Biology; Tatiana Novobrantseva, Stuart Milstein, Hila Epstein-Barash, William Cantley, Jamie Wong, and Victor Koteliansky, Alnylam Pharmaceuticals; Kang Mi Lee, James Kim and James Markmann, MGH Department of Surgery; Peter Panizzi, Auburn University; Won Woo Lee, Seoul National University; Kevin Love, Massachusetts Institute of Technology; and Peter Libby, Brigham and Women's Hospital. The study was supported by grants from the National Institute of Health and other funders.
Celebrating the 200th anniversary of its founding in 1811, Massachusetts General Hospital (www.massgeneral.org) is the original and largest teaching hospital of Harvard Medical School. MGH conducts the largest hospital-based research program in the United States, with an annual research budget of nearly $700 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.
END
One of the most successful strategies in pest control is to endow crop plants with genes from the bacterium Bacillus thuringiensis, or Bt for short, which code for proteins that kill pests attempting to eat them.
But insect pests are evolving resistance to Bt toxins, which threatens the continued success of this approach. In the current issue of Nature Biotechnology, a research team led by UA Professor Bruce Tabashnik reports the discovery that a small modification of the toxins' structure overcomes the defenses of some major pests that are resistant to the natural, ...
Aircraft Management Group, Inc., branded as AMG Jets, is pleased to announce the expansion of its team to include two new members. These members include Shannon Pennypacker, appointed as Director of Marketing and Sales; and Lynne Cone, appointed as a private aviation specialist.
This expansion is in response to the increasing demand level and sales growth last year. "We have experienced consistent growth year after year," said President John Sieckowski. "The increase in our team will help us to keep up with the growing demand of our wide range of services."
Shannon ...
An international team of researchers has discovered the first DNA faults linked to melanoma - the deadliest skin cancer - that are not related to hair, skin or eye colour.
Cancer Research UK scientists at the University of Leeds, together with a team from the GenoMEL consortium*, scanned the genes in blood samples from almost 3000 Europeans with melanoma, and compared these with samples taken from the general population.
Their findings are published in Nature Genetics today.**
Known risk factors for melanoma include fair skin, blue or green eyes, blond or red hair, ...
The world's thinnest, strongest and most conductive material, discovered in 2004 at the University of Manchester by Professor Andre Geim and Professor Kostya Novoselov, has the potential to revolutionize material science.
Demonstrating the remarkable properties of graphene won the two scientists the Nobel Prize for Physics last year and Chancellor of the Exchequer George Osborne has just announced plans for a £50m graphene research hub to be set up.
Now, writing in the journal Nature Physics, the University of Manchester team have for the first time demonstrated how graphene ...
The genomic analysis technologies enable the study of genetic factors related to numerous diseases. In few areas this researches brought such a big and useful volume of information as in the case of melanoma. A study published in Nature Genetics, promoted by the GenoMEL consortium, consolidates the results obtained in previous whole-genome analysis and identifies three new chromosomal regions implicated in susceptibility to melanoma. The GenoMEL consortium is funded by the European Commission and the National Institutes of Health (USA) to increase the understanding of genetic ...
MADISON – An ongoing lack of sleep during adolescence could lead to more than dragging, foggy teens, a University of Wisconsin-Madison study suggests.
Researchers have found that short-term sleep restriction in adolescent mice prevented the balanced growth and depletion of brain synapses, connections between nerve cells where communication occurs.
"One possible implication of our study is that if you lose too much sleep during adolescence, especially chronically, there may be lasting consequences in terms of the wiring of the brain," says Dr. Chiara Cirelli, associate ...
New York University biologists have identified a new mechanism for regulating color vision by studying a mutant fly named after Frank ('Ol Blue Eyes) Sinatra. Their findings, which appear in the journal Nature, focus on how the visual system functions in order to preserve the fidelity of color discrimination throughout the life of an organism. They also offer new insights into how genes controlling color detection are turned on and off.
Many biologists study how different cells develop to acquire their fate. The NYU research team, headed by Claude Desplan, a professor ...
All cells in our body have a system that can handle cellular waste and release building blocks for recycling. The underlying mechanism is called autophagy and literally means "self-eating". Many cancer cells have increased the activity of this system and the increased release of building blocks equip the cancer cells with a growth advantage and can render them resistant towards treatment.
"We have discovered a small molecule that can block autophagy in different cancer cells and specifically, this molecule can increase the sensitivity of breast cancer cells towards one ...
24-7PressRelease.com announces today that it has reached a milestone, having distributed 175,000 press releases to date.
"The news is exciting for the company," said Michael Iwasaki, Managing Partner with 24-7PressRelease. "We continue to expand and grow in popularity with marketing, PR and communications companies looking for excellent value combined with excellent customer service. The economy is still in extreme turmoil. We are continually receiving positive feedback."
The company also offers website owners the option to add their top news ...
A new study has found that an osteoporosis drug protects against the bone damaging side effects of certain breast cancer medications. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that some breast cancer patients could take zoledronic acid in addition to their anti-cancer medications to maintain bone health.
Drugs called aromatase inhibitors stop the production of estrogen in postmenopausal women and therefore make less estrogen available to stimulate the growth of certain breast cancer cells. Many postmenopausal ...
